Kevin Gunderson Email & Phone Number

Providing scientific and technical consulting services to biotech companies with emphasis on tools development.

San Diego, Ca, Us

San Diego, Ca, Us

Encodia is enabling “Next-Gen” proteomics by creating scalable and parallelized solutions to protein analysis.

San Diego, Ca, Us

Oversaw R&D of new genotyping and sequencing technologies and applications.Led Advanced Research team developing array-based and Next-Gen sequencing technologies. Array technologies that we developed include development of various Infinium-based product lines (genotyping, DNA copy number, methylation and FFPE analysis) generating over $1B in sales.He and his team also developed a variety of novel Next-Gen libary preparation approaches which have enabled improved targeted sequencing, long range haplotyping, and single cell analysis. For targeted enrichment, Kevin's team developed both a hybrid capture approach to DNA enrichment used in Illumina’s TruSeq and Nextera rapid capture enrichment kits, and additionally conceived and developed the TruSeq Custom amplicon assay. Kevin's team also conceived and developed several synthetic long read technologies which enable long range sequence information to be inferred from short read Next-Gen sequencing. These technologies include combinatorial indexing-based CPT-Seq and barcoded bead-based CPT-Seq (see publications). Expanding on the CPT-Seq combinatorial indexing approach, Kevin and his team initiated a collaboration with Jay Shendure’s lab to develop transposase-based single cell combinatorial indexing approaches to single cell analysis (SCI-seq). Populations of nuclei are combinatorially indexed to generate single cell nuclei libraries. Depending on how the nuclei are processed, various types of single cell libraries can be generated including sci-ATAC-seq for measuring chromatin accessibility, sci-Hi-C for measuring chromatin structure, sci-DNA-seq for measuring copy number, as well as enabling a variety other single cell indexed nuclei-based studies. Finally, Kevin’s Advanced Research team also led the initial microfabrication development of patterned flow cells, which form the core of the Illumina’s highly successful HiSeq and NovaSeq product lines.

San Diego, Ca, Us

Kevin and his team invented and developed Illumina’s Infinium® whole genome genotyping assay enabling virtually unlimited multiplexing from a single sample preparation. Using this technology, Illumina has developed a high-density SNP genotyping platform capable of genotyping over 20 million SNPs on a single slide. His team also combined the Infinium assay with bisulfate conversion to create a genome-wide assay for CpG methylation. Moreover, he and his team developed several Infinium applications including DNA copy number, methylation and FFPE analysis. Accomplishments include release of the Infinium Methylation assay which is used in the highly successful Infinium HumanMethylation 450k BeadChip, and the InfiniumFFPE Restoration kit. Kevin and his team also played a key role in identifying NGS as an important business opportunity for Illumina prior to the Solexa acquisition.

San Diego, Ca, Us

Developed BeadArray decoding and genotyping platforms.

San Diego, Ca, Us

Initial founding scientist at Illumina. Developed decoding and genotyping platforms, and received several patents for work. Conceived the idea of applying error correcting codes such as Hamming distance to improve accuracy of decoding.

Santa Clara, California, Us

Developed sequencing by hybridization/ligation approaches on n-mer arrays. We demonstrated the first example of sequencing by hybridization by resequencing up to 5000 base targets using arrays of all possible 9-mer DNA words.

Executive Perspective For Scientists & Engineers (Epse)

Ph.D., Biophysics

M.S., Physics

Ba, Physics And Math